| Literature DB >> 30365826 |
Ligia Fidelis Ivanovic1, Bruno C Silva2, Arnaldo Lichtenstein1, Edison Ferreira de Paiva1, Maria Lucia Bueno-Garcia1.
Abstract
OBJECTIVES: To describe clinical complications related to colonoscopy in inpatients with multiple diseases. Among the known complications, acute kidney injury was the primary focus.Entities:
Mesh:
Year: 2018 PMID: 30365826 PMCID: PMC6172976 DOI: 10.6061/clinics/2018/e456
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Demographics, comorbidities and medications used as stratified by the colonoscopy indication.
| Covariate | All patients (N=97) | Screening group (N=9) | Diagnostic group (N=88) | |
|---|---|---|---|---|
| Age, years (min; max) | 71 (19; 87) | 70 (61; 79) | 71 (19; 87) | 0.886 |
| Gender, % (N) | ||||
| Male | 37.4% (46) | 33.3% (3) | 48.9% (43) | 0.374 |
| Female | 41.5% (51) | 66.7% (6) | 51.1% (45) | 0.374 |
| Length of hospital stay, days (min; max) | 10 (3; 86) | 6 (3; 14) | 10 (3; 86) | 0.022 |
| Comorbidities, % | ||||
| Diabetes | 45.4% | 100% | 39.8% | 0.001 |
| Heart disease | 26.8% | 22.2% | 27.3% | 0.745 |
| Cerebrovascular disease | 14.4% | 11.1% | 14.8% | 0.766 |
| Regular medications, % | ||||
| ACEI | 49.5% | 100% | 44.3% | 0.001 |
| Diuretic | 36.1% | 77.8% | 31.8% | 0.006 |
| Calcium channel blocker | 28.9% | 55.6% | 26.1% | 0.064 |
| Beta blocker | 30.9% | 44.4% | 29.5% | 0.357 |
| Aspirin | 27.8% | 33.3% | 27.3% | 0.699 |
| Statin | 36.1% | 66.7% | 33% | 0.045 |
| Insulin | 15.1% | 55.6% | 11.4% | 0.000 |
All patients: all participants in the study; Screening group: patients who underwent a screening colonoscopy; Diagnostic group: patients who underwent a diagnostic colonoscopy; N: sample size. Continuous data are expressed as the mean±SD; non-parametric data are expressed as the median (minimum, maximum).
Laboratory data as stratified by colonoscopy indication.
| Blood test | All patients | Screening group | Diagnostic group | |
|---|---|---|---|---|
| Blood glucose, mg/dL (min; max) | 109 (50; 437) (N=89) | 203 (84; 437) (N=9) | 106.5 (50; 237) (N=80) | 0.001 |
| Glycated Haemoglobin, % (min; max) | 6.25 (4.7; 14.5) (N=44) | 9.04 (5.3; 14.5) (N=7) | 6.2 (4.7; 9.4) (N=37) | 0.024 |
| LDL cholesterol, mg/dL (min; max) | 110 (45; 267) (N=60) | 119 (84; 147) (N=9) | 110 (45; 267) (N=51) | 0.310 |
| Creatinine pre, mg/dL | 1.12±1.11 | 1.14±0.46 | 1.12±1.16 | 0.252 |
| CKD-EPI pre, mL/min | 71.7±28.02 | 60.67±20.73 | 72.93±28.51 | 0.179 |
| Creatinine post, mg/dL | 1.38±1.18 | 1.51±0.58 | 1.37±1.22 | 0.104 |
| CKD-EPI post, mL/min | 61.86±31.9 | 43.67±17.57 | 63.72±32.61 | 0.075 |
All patients: all participants of the study; Screening group: patients submitted to screening colonoscopy; Diagnostic group: patients submitted to diagnostic colonoscopy; N: sample size; pre, before colonoscopy; post, after colonoscopy; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration. Continuous parametric data are expressed as the mean±SD; non-parametric data are expressed as the median (minimum, maximum).
Complications of colonoscopy as stratified by colonoscopy indication.
| Complications | All patients (N=97) | Screening group (N=9) | Diagnostic group (N=88) | |
|---|---|---|---|---|
| All events %, (N) | 53.6% (52) | 77.8% (7) | 51.1% (45) | 0.127 |
| Sepsis, % (N) | 2.1% (2) | 0 | 2.3% (2) | 0.648 |
| Hypotension, % (N) | 5.2% (5) | 0 | 5.7% (5) | 0.463 |
| Cardiovascular events | 2.1% (2) | 0 | 2.3% (2) | 0.648 |
| Inadequate bowel preparation, % (N) | 15.5% (15) | 22.2% (2) | 14.8% (13) | 0.556 |
| Suspended exam, % (N) | 2.1% (2) | 0 | 2.3% (2) | 0.648 |
| Hypoglycaemia, % (N) | 1% (1) | 11.1% (1) | 0 | 0.002 |
| Nausea/vomiting/sub-occlusion, % (N) | 2.1% (2) | 0 | 2.3% (2) | 0.648 |
| Acute kidney injury, % (N) | 41.2% (40) | 66.7% (6) | 38.6% (34) | 0.104 |
| Time to acute kidney injury, days±SD | 1.11±1.49 | 1.17±1.72 | 1.27±1.52 | 0.924 |
| Cancer, % (N) | 3.3% (4) | 0 | 4.5% (4) | 0.514 |
| Low grade adenoma, % (N) | 16.3% (20) | 22.2% (2) | 19.3% (17) | 0.834 |
| Moderate grade adenoma, % (N) | 7.1% (7) | 11.1% (1) | 6.8% (6) | 0.635 |
| Severe grade adenoma, % (N) | 2.1% (2) | 11.1% (1) | 11.1% (1) | 0.758 |
All patients: all participants in the study; Screening group: patients who underwent a screening colonoscopy; Diagnostic group: patients who underwent a diagnostic colonoscopy; N: sample size.
Colonoscopy-related complications according to the CKD-EPI glomerular filtration rate.
| Covariate | CKD-EPI ≥60 | CKD-EPI 30-59 | |
|---|---|---|---|
| Age, years (min; max)** | 67 (19; 84) | 72 (58; 85) | 0.004 |
| Length of hospital stay, days (min; max)** | 11 (3; 86) | 9 (3; 84) | 0.22 |
| Blood glucose, mg/dL (min; max)** | 106 (50; 325) | 113 (61; 252) | 0.45 |
| Glycated haemoglobin, % (min; max)** | 6.2 (4.7; 9.8) | 6.2 (5.1; 9.4) | 0.68 |
| LDL, mg/dL (min; max)** | 119 (47; 267) | 100 (45; 198) | 0.17 |
| Time to acute kidney injury, days**MedianMinimum, maximum***Mean±SD* | 1-1, 51.17±1.68 | 1-1, 41.21±1.12 | 0.40 |
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration *Parametric data expressed as the mean±SD and tested by T Test; **non-parametric data expressed as median (minimum, maximum) and tested by Mann-Whitney test; ***Time to development of acute kidney injury, in days, considering zero as the day of the exam. Negative numbers refer to development of kidney injury before the date of the exam, during the preparation.